Trial Profile
A randomised phase II pilot study of 3 weekly Cabazitaxel versus weekly Paclitaxel chemotherapy in the first line treatment of HER2 negative metsastatic breast cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary) ; Paclitaxel
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms CONCEPT
- Sponsors Sanofi
- 08 Jun 2021 Status changed from recruiting to completed as per results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 11 Nov 2019 Planned number of patients changed from 90 to 160.